Skip to main content Skip to main navigation menu Skip to site footer

The effect of MLC901 therapy on neutrophil-to-lymphocyte-ratio, platelet-to-lymphocyte-ratio, BDNF, MoCA-INA score, and Barthel-index score in traumatic brain injury patients

  • Gede Febby Pratama Kusuma ,
  • Sri Maliawan ,
  • Tjokorda Gde Bagus Mahadewa ,
  • Ni Nyoman Sri Budayanti ,
  • Tjokorda Gde Agung Senapathi ,
  • Anak Agung Ayu Putri Laksmidewi ,


Background: An intervention is needed to prevent secondary-brain-injury (SBI) post-traumatic-brain-injury (TBI) and improved the patient’s clinical outcome. Recent pre-clinical studies found that MLC901, a phytopharmaceutical supplement, has the neuroprotective and neuroregenerative potential to prevent SBI post-TBI. This study aimed to clinically prove the neuroprotection and neuroregeneration effects of MLC901 therapy on TBI through the neutrophil-to-lymphocyte-ratio (NLR), platelet-to-lymphocyte-ratio (PLR), BDNF, MoCA-INA score and Barthel-Index (BI) score.

Methods: A randomized-control-group pretest-posttest study in TBI-patients was conducted. Patients were divided randomly into control (standard therapy) and treatment (MLC901 and standard therapy) groups. All of the patient was treated and followed prospectively. The patient’s data such as age, sex, Glasgow coma scale (GCS) score, educational status, NLR, PLR, BDNF levels, BI and MoCA-INA scores were documented and analyzed to get the results.

Results: There were no significant characteristic differences between groups before the therapy started. Combination of MLC901 and standard therapy significantly reduced the NLR levels on day-7th (4.68±2.01 vs. 9.72±6.70; p=0.003) and day-30th post-TBI (2.20±0.89 vs. 5.58±4.68; p=0.005), reduced the PLR levels on day-30th post-TBI (137.82±29.66 vs. 213.39±147.49; p=0.031), increased the BI score on day-7th (77.86±23.54 vs. 27.62±27.51; p=0.0001) and day-30th post-TBI (99.52±2.18 vs. 61.43±36.92; p=0.0001), and increased the MoCA-INA score on day-7th (21.10±7.62 vs. 6.24±8.83; p=0.0001) and day-30th post-TBI (27.24±3.13 vs. 12.57±9.40; p=0.0001) compared to the standard therapy alone. There was no significant mean difference in BDNF levels between groups although the treatment group had higher mean BDNF levels compared to the control group.

Conclusion: This study proved the benefits of MLC901 therapy as a neuroprotective agent through the anti-neuroinflammatory pathway by reducing the NLR and PLR levels in TBI patients, thus preventing the occurrence of SBI post-TBI and improving the activity of daily living and cognitive function of TBI patients.


  1. Williams OH, Tallantyre EC, Robertson NP. Traumatic brain injury: Pathophysiology, clinical outcome and treatment. J Neurol. 2015;262:1394-6.
  2. Liu YW, Li S, and Dai SS. Neutrophils in traumatic brain injury (tbi): Friend or foe? J Neuroinflammation. 2018;15:146.
  3. Moppett IK. Traumatic brain injury: Assessment, resuscitation and early management. Br J Anaesth. 2007;99:18-31.
  4. Fang J, Han D, Hong J, Tan Q, Tian Y. The chemokine, macrophage inflammatory protein-2gamma, reduces the expression of glutamate transporter-1 on astrocytes and increases neuronal sensitivity to glutamate excitotoxicity. J Neuroinflammation. 2012;9:267.
  5. Kalish H, Phillips TM. Application of immunoaffinity capillary electrophoresis to the measurements of secreted cytokines by cultured astrocytes. J Sep Sci. 2009;32:1605-12.
  6. Liu Z, Chopp M. Astrocytes, therapeutic targets for neuroprotection and neurorestoration in ischemic stroke. Prog Neurobiol. 2016;144:103-20.
  7. Loane DJ, Kumar A. Microglia in the tbi brain: The good, the bad, and the dysregulated. Exp Neurol. 2016;275:316-27.
  8. Lu KT, Wang YW, Yang JT, Yang YL, Chen HI. Effect of interleukin-1 on traumatic brain injury-induced damage to hippocampal neurons. J Neurotrauma. 2005;22:885-95.
  9. Pineau I, Sun L, Bastien D, Lacroix S. Astrocytes initiate inflammation in the injured mouse spinal cord by promoting the entry of neutrophils and inflammatory monocytes in an il-1 receptor/myd88-dependent fashion. Brain Behav Immun. 2010;24:540-53.
  10. Xiong Y, Zhang Y, Mahmood A, Chopp M. Investigational agents for treatment of traumatic brain injury. Expert Opin Investig Drugs. 2015;24:743-60.
  11. Mishra RK, Galwankar S, Gerber J, Jain A, Yunus M, Cincu R, et al. Neutrophil-lymphocyte ratio as a predictor of outcome following traumatic brain injury: Systematic review and meta-analysis. J Neurosci Rural Pract. 2022;13(4):618-35.
  12. Liu H, Zhang X. Correlation between platelet parameters, platelet/lymphocyte ratio, the severity and prognosis of patients with traumatic brain injury. Int J Clin Exp Med. 2020;13(7):5187-92.
  13. Mauritz W, Wilbacher I, Majdan M, Leitgeb J, Janciak I, Brazinova A, et al. Epidemiology, treatment and outcome of patients after severe traumatic brain injury in european regions with different economic status. Eur J Public Health. 2008;18:575-80.
  14. Bullock MR, Povlishock JT. Guidelines for the management of severe traumatic brain injury. J Neurotrauma. 2007;24:2 p preceding S1.
  15. Heurteaux C, Widmann C, Moha ou Maati H, Quintard H, Gandin C, Borsotto M, et al. Neuroaid: Properties for neuroprotection and neurorepair. Cerebrovasc Dis. 2013;35:1-7.
  16. Quintard H, Lorivel T, Gandin C, Lazdunski M, Heurteaux C. Mlc901, a traditional chinese medicine induces neuroprotective and neuroregenerative benefits after traumatic brain injury in rats. Neuroscience. 2014;277:72-86.
  17. Widmann C, Gandin C, Petit-Paitel A, Lazdunski M, Heurteaux C. The traditional chinese medicine mlc901 inhibits inflammation processes after focal cerebral ischemia. Sci Rep. 2018;8:18062.
  18. Gandin C, Widmann C, Lazdunski M, Heurteaux C. Mlc901 favors angiogenesis and associated recovery after ischemic stroke in mice. Cerebrovasc Dis. 2016;42:139-54.
  19. Heurteaux C, Gandin C, Borsotto M, Widmann C, Brau F, Lhuillier M, et al. Neuroprotective and neuroproliferative activities of neuroaid (mlc601, mlc901), a chinese medicine, in vitro and in vivo. Neuropharmacology. 2010;58:987-1001.
  20. Quintard H, Borsotto M, Veyssiere J, Gandin C, Labbal F, Widmann C, et al. Mlc901, a traditional chinese medicine protects the brain against global ischemia. Neuropharmacology. 2011;61:622-31.
  21. Mattson MP. Glutamate and neurotrophic factors in neuronal plasticity and disease. Ann N Y Acad Sci. 2008;1144:97-112.
  22. Volosin M, Song W, Almeida RD, Kaplan DR, Hempstead BL, Friedman WJ. Interaction of survival and death signaling in basal forebrain neurons: Roles of neurotrophins and proneurotrophins. J Neurosci. 2006;26:7756-66.
  23. Maati HMO, Borsotto M, Chatelain F, Widmann C, Lazdunski M, and Heurteaux C. Activation of atp-sensitive potassium channels as an element of the neuroprotective effects of the traditional chinese medicine mlc901 against oxygen glucose deprivation. Neuropharmacology. 2012;63:692-700.
  24. Lindblad C, Thelin EP, Nekludov M, Frostell A, Nelson DW, Svensson M, et al. Assessment of platelet function in traumatic brain injury-a retrospective observational study in the neuro-critical care setting. Front Neurol. 2018;9:15.
  25. Zhang W, Shen Y. Platelet-to-lymphocyte ratio as a new predictive index of neurological outcomes in patients with acute intracranial hemorrhage: A retrospective study. Med Sci Monit. 2018;24:4413-20.
  26. Rosyidi RM. Pengaruh pemberian mlc 901 terhadap ekspresi mrna bdnf, kadar bdnf, kadar tnf-α dan gambaran histopatologis otak pada tikus sprague dawley yang mengalami cedera otak traumatik. Makasar: Universitas Hasanuddin; 2020.
  27. Bathina S, Das UN. Brain-derived neurotrophic factor and its clinical implications. Arch Med Sci. 2015;11:1164-78.
  28. Wurzelmann M, Romeika J, Sun D. Therapeutic potential of brain-derived neurotrophic factor (bdnf) and a small molecular mimics of bdnf for traumatic brain injury. Neural Regen Res. 2017;12:7-12.
  29. Wang X, Gao X, Michalski S, Zhao S, Chen J. Traumatic brain injury severity affects neurogenesis in adult mouse hippocampus. J Neurotrauma. 2016;33:721-33.
  30. Kumar R, Abu Bakar A, Thanabalan J, Paramasvaran S, Toh CJ, Jaffar A, et al. Safety and use of mlc601/mlc901 (neuroaid(tm)) in primary intracerebral hemorrhage: A cohort study from the neuroaid safe treatment registry. Brain Sci. 2020;10.
  31. Theadom A, Barker-Collo S, Jones KM, Parmar P, Bhattacharjee R, Feigin VL. Mlc901 (neuroaid ii) for cognition after traumatic brain injury: A pilot randomized clinical trial. Eur J Neurol. 2018;25:1055-e82.

How to Cite

Kusuma, G. F. P., Maliawan, S., Mahadewa, T. G. B., Budayanti, N. N. S., Senapathi, T. G. A., & Laksmidewi, A. A. A. P. (2024). The effect of MLC901 therapy on neutrophil-to-lymphocyte-ratio, platelet-to-lymphocyte-ratio, BDNF, MoCA-INA score, and Barthel-index score in traumatic brain injury patients. Bali Medical Journal, 13(3), 1040–1044.




Search Panel

Gede Febby Pratama Kusuma
Google Scholar
BMJ Journal

Sri Maliawan
Google Scholar
BMJ Journal

Tjokorda Gde Bagus Mahadewa
Google Scholar
BMJ Journal

Ni Nyoman Sri Budayanti
Google Scholar
BMJ Journal

Tjokorda Gde Agung Senapathi
Google Scholar
BMJ Journal

Anak Agung Ayu Putri Laksmidewi
Google Scholar
BMJ Journal